Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Arthritis Rheum. 2011 Mar;63(3):573–586. doi: 10.1002/art.30129

Table 4.

Face Validity. Prevalence of remission (%) in recent trials of patients with rheumatoid arthritis.*

Remission definition DMARD
monotherapy
(n=380)
Biological
monotherapy
(n=520)
Combination
Therapy
(n=330)
Total

(n=1230)
TJC,SJC,CRP,PtGA 9 7 22 12
TJC,SJC,CRP,PtGA,pain 8 6 20 12
TJC,SJC,CRP,PhGA,PtGA 8 7 20 10
TJC,SJC,CRP,PhGA,pain 8 6 20 10
TJC,SJC,CRP,PhGA,PtGA,pain 7 6 18 9
DAS28 <2.6 19 17 35 21
DAS28<2.0 5 8 24 10
SDAI ≤ 3.3 10 8 26 14
*

Abbreviations as defined in Tables 1 and 3A.

Pooled data from ERA, PREMIER and TEMPO trials.34,37,38